Literature DB >> 21958304

HBeAg and not genotypes predicts viral load in patients with hepatitis B in Denmark: a nationwide cohort study.

Henrik Krarup1, Stig Andersen, Poul Henning Madsen, Peer Brehm Christensen, Alex Lund Laursen, Anne Bentzen-Petersen, Jørn M Møller, Nina Weis.   

Abstract

OBJECTIVE: To explore the influence of HBV genotype on viral load in patients with HBV infection, and to investigate the relation to gender, age and country of origin or antibodies against hepatitis Be antigen (anti-HBe). MATERIALS: We investigated 1025 patients with hepatitis B virus infection in a nationwide study in Denmark.
RESULTS: Prevalence of genotypes were: 10.5% A, 17.3% B, 20.5% C, 45.7% D, 3.2% E, 0.6% F, 1.1% G and 1% had more than one genotype. Nearly 60% of patients with genotype A were from Africa, 82% and 93% with genotypes B or C were from East Asia, 62% with genotype D came from the Middle East and 91% with genotype E came from Africa. More women had genotypes B (p = 0.006) or C (p < 0.001) while more men had genotypes A (p = 0.015) or D (p < 0.001). Women with genotypes B and D were younger than men (p < 0.001, p = 0.026). Viral load differed in genotype A and D compared with B and C (p < 0.001), and between anti-HBe and hepatitis B e antigen (HBeAg) positive patients (median values 5.4 × 10(3) IU/ml and 7.4 × 10(7) IU/ml, respectively, p < 0.001). Viral load depended on the presence of HBeAg (p < 0.001; OR, 95% CI: 0.05, 0.03-0.07) in the adjusted analysis and was not affected by origin (p = 0.65), age (p = 0.12), gender (p = 0.06) or genotype (p = 0.10).
CONCLUSION: HBeAg status and not HBV genotype influenced viral load in this nationwide study. HBeAg positive patients had median HBV-DNA levels 10,000 times higher than those anti-HBe positive across genotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958304     DOI: 10.3109/00365521.2011.619273

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

1.  Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.

Authors:  Chloe L Thio; Laura Smeaton; Melissa Saulynas; Hyon Hwang; Shanmugam Saravanan; Shanmugam Saravan; Smita Kulkarni; James Hakim; Mulinda Nyirenda; Hussain S Iqbal; Umesh G Lalloo; Anand S Mehta; Kimberly Hollabaugh; Thomas B Campbell; Shahin Lockman; Judith S Currier
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

2.  Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana.

Authors:  Motswedi Anderson; Simani Gaseitsiwe; Sikhulile Moyo; Kerapetse P Thami; Terence Mohammed; Ditiro Setlhare; Theresa K Sebunya; Eleanor A Powell; Joseph Makhema; Jason T Blackard; Richard Marlink; Max Essex; Rosemary M Musonda
Journal:  Open Forum Infect Dis       Date:  2016-08-16       Impact factor: 3.835

3.  Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV.

Authors:  Nanna-Sophie Brinck-Jensen; Thomas Vorup-Jensen; Peter Derek Christian Leutscher; Christian Erikstrup; Eskild Petersen
Journal:  BMC Immunol       Date:  2015-11-02       Impact factor: 3.615

4.  Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22-23 March 2012.

Authors:  David FitzSimons; Brian McMahon; Greet Hendrickx; Alex Vorsters; Pierre Van Damme
Journal:  Int J Circumpolar Health       Date:  2013-07-17       Impact factor: 1.228

5.  Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.

Authors:  Bo Langhoff Hønge; Sanne Jespersen; Candida Medina; David da Silva Té; Zacarias José da Silva; Sharon Lewin; Lars Østergaard; Christian Erikstrup; Christian Wejse; Alex Lund Laursen; Henrik Krarup
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.